Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term im [Immunology]. Found 5 abstracts

Mu Z, Hachem P, Pollack A. Antisense Bcl-2 sensitizes prostate cancer cells to radiation. The Prostate. 2005 Dec;65(4):331-40.
Wen L, Brill-Dashoff J, Shinton SA, Asano M, Hardy RR, Hayakawa K. Evidence of marginal-zone B cell-positive selection in spleen.[see comment]. Immunity. 2005 Sep;23(3):297-308.
Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.[see comment]. Cancer Research. 2004 Sep;64(17):6200-6.
Borghaei H, Wallace SG, Schilder RJ. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Clinical Lymphoma. 2004 Oct;5 Suppl 1:S16-21.
Milling SW, Sai T, Silvers WK, Mintz B. Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells. Melanoma Research. 2004 Dec;14(6):555-62.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term im [Immunology]

im [Immunology] Non-US Gov't Research Support rt [Radiotherapy] me [Metabolism] Mice ge [Genetics] th [Therapy] Yttrium Radioisotopes Radioimmunotherapy 0 (Yttrium Radioisotopes) bi [Biosynthesis] Flow Cytometry pd [Pharmacology] Tumor Cell Line Transgenic Mice pa [Pathology] EC 3-4-22 (caspase-3) NIH Research Support-Extramural re [Radiation Effects] ae [Adverse Effects] Clonal Deletion Pentetic Acid Tissue Distribution cy [Cytology] tu [Therapeutic Use] Cell Proliferation 0 (Immunotoxins) Immunoglobulin Variable Region CD20 Antigens ai [Antagonists & Inhibitors] Non-Hodgkin Lymphoma Proto-Oncogene Proteins c-bcl-2 Prostatic Neoplasms Nude Mice Thy-1) 0 (Antigens Cyclin-Dependent Kinase Inhibitor p21 Fluorescent Antibody Technique Macrophages Enzyme-Linked Immunosorbent Assay N' -N-N'-N''-N''-pentaacetic acid) Treatment Outcome 0 (Neoplasm Proteins) Cell Differentiation 0 (Immunoglobulin G) 0 (Tumor Suppressor Protein p53) Cultured Cells 0 (ibritumomab tiuxetan) Risk Factors Experimental Melanoma erbB-2) EC 2-7-1-112 (Receptor CD4-Positive T-Lymphocytes Combined Modality Therapy 0 (Peptide Fragments) 0 (Cytokines) 0 (Immunoglobulin Variable Region) 0 (Cyclin-Dependent Kinase Inhibitor p21) Tumor Suppressor Protein p53 Simian virus 40 Tumor-Infiltrating Lymphocytes 0 (notch2 receptor) Inbred C57BL Mice Male Monoclonal Antibodies Immunoglobulin G Comparative Study Cell Surface) 0 (Receptors CD20) 0 (Antigens 2-diamine (N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1 Female ri [Radionuclide Imaging] Monophenol Monooxygenase ad [Administration & Dosage] Prognosis Immunologic Cytotoxicity Tests Xenograft Model Antitumor Assays Autoantibodies 0 (Autoantigens) 142434-84-2 Ovarian Neoplasms Apoptosis 0 (Proto-Oncogene Proteins c-bcl-2) mt [Methods] Monoclonal) 0 (Antibodies SCID Mice EC 3-4-22 (Caspases) 0 (Isothiocyanates) Transfection Antisense) 0 (DNA EC 1-14-18-1 (Monophenol Monooxygenase) Antigen Receptors-B-Cell Dendritic Cells Spleen Cytokines Thy-1 Antigens pk [Pharmacokinetics] EC 3-4-22 (caspase 7) Antigen 0 (Receptors-B-Cell) 67-43-6 (Pentetic Acid) bl [Blood] Skin Neoplasms Neoplasm Proteins Immunotoxins Autoantigens Antisense DNA Cytotoxic T-Lymphocytes human) 0 (TP53 protein B-Lymphocytes Cell Surface Receptors aa [Analogs & Derivatives] erbB-2 Receptor Isothiocyanates Peptide Fragments Breast Neoplasms 0 (Autoantibodies) CD8-Positive T-Lymphocytes Caspases 0 (Melan-A protein) Second Primary Neoplasms Cell Line
Last updated on Thursday, April 02, 2020